TheStreet's Martin Baccardax noted that Eli Lilly said that donanemab, an investigational antibody, showed a 32% reduction in a composite measure of cognition and daily function in trial patients suffering early symptomatic Alzheimer's disease following Phase 2 trials. Eli Lilly had said on January 11 that the 32% decline rate, compared to placebo, was 'statistically significant' and met the primary endpoint of phase 2 'Trailblazer' ALZ study.
"Given our conversations with investors when the data first came out, it was clear that expectations were relatively high, which seemed strange to us given the lack of the detailed data and the continuous disappointments in the AD space," said SVB Leerink analyst Marc Goodman. "Given our critical view of the full data set, we do think that the totality of the TRAILBLAZER-ALZ data is still supportive of the anti-Abeta hypothesis, given the significant Abeta clearance and consistently positive trend across several important endpoints, but demonstrating correlation with cognitive endpoints with a prespecified endpoint will still be a challenge."
For more on Lilly, catch Jim Cramer's Action Alerts PLUS Daily Rundown.
Recap TheStreet Live: Everything Jim Cramer Is Watching in the Markets Monday